Receptor Tyrosine Kinase Inhibitor ABT-869
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Enzyme Inhibitor ->
Protein Kinase Inhibitor ->
Tyrosine Kinase Inhibitor -> Receptor Tyrosine Kinase Inhibitor ABT-869
Receptor Tyrosine Kinase Inhibitor ABT-869 Definition
An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Receptor tyrosine kinase inhibitor ABT-869 inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, ABT-869 may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
Receptor Tyrosine Kinase Inhibitor ABT-869 Synonyms
Receptor Tyrosine Kinase Inhibitor ABT-869, ABT-869
Terms in Receptor Tyrosine Kinase Inhibitor ABT-869 category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.